Welcome to our dedicated page for Werewolf Therapeutics SEC filings (Ticker: HOWL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Werewolf Therapeutics SEC filings document material events, operating results, governance matters, and capital-structure disclosures for a Delaware biopharmaceutical company developing conditionally activated immune therapeutics. Recent 8-K filings furnish quarterly financial results, press-release exhibits, and updates tied to the company’s PREDATOR, INDUKINE, and INDUCER programs.
The filings also cover Nasdaq continued-listing matters, audit committee composition, exit and disposal activities, emerging growth company status, common stock registered under the HOWL symbol, shareholder voting matters, clinical and regulatory disclosures, and risk language related to strategy, operations, development plans, and corporate alternatives.
Werewolf Therapeutics (HOWL): Insider transactions disclosed. An affiliated group led by MPM BioImpact reported open‑market sales of common stock on three dates under a Rule 10b5‑1 plan dated September 24, 2025.
Across 11/04/2025, 11/05/2025, and 11/06/2025, the group sold a combined 242,890 shares, at weighted‑average prices of $1.22, $1.22, and $1.21, respectively. Reported price ranges were $1.17–$1.30, $1.19–$1.25, and $1.185–$1.27. Following these transactions, the reporting persons indirectly beneficially owned 5,904,720 shares.
The filing notes the reporting person is a director and 10% owner, and that sales were allocated among affiliated entities including MPM Asset Management LLC, MPM BioVentures 2014, L.P., MPM BioVentures 2014(B), L.P., MPM Asset Management Investors BV2014 LLC, MPM Oncology Innovations Fund, L.P., and UBS Oncology Impact Fund L.P.
Werewolf Therapeutics (HOWL) reported insider stock sales by affiliated reporting persons. The group executed open‑market sales under a Rule 10b5‑1 plan dated September 24, 2025. Transactions included 140,488 shares on November 4 at a weighted average price of $1.22, 47,950 shares on November 5 at $1.22, and 54,452 shares on November 6 at $1.21.
Following these trades, the reporting persons collectively reported 5,904,720 shares beneficially owned on an indirect basis. The filing indicates the reporting persons are a director and 10% owner, and that the submission was made by more than one reporting person.
Werewolf Therapeutics (HOWL) filed its Q3 2025 report, highlighting continued operating losses and a liquidity warning. The company reported a Q3 net loss of $16.4 million and a nine‑month net loss of $52.4 million. Revenue was $0 for the quarter and year‑to‑date, following prior collaboration revenue in 2024.
Cash and cash equivalents were $65.7 million as of September 30, 2025, down from $111.0 million at year‑end 2024, after $49.3 million used in operating activities year‑to‑date. Management states there is substantial doubt about the company’s ability to continue as a going concern and is evaluating options to raise additional capital. The company sold 2,360,186 shares via its ATM for net proceeds of $3.6 million in the first nine months.
R&D expense was $11.6 million and G&A was $4.1 million in Q3. Debt includes a $30.0 million K2HV term loan at a coupon of 10.3% (effective rate disclosed at 19.24%) and a related derivative liability of $2.6 million. Clinical programs continue: WTX‑124 is in Phase 1/1b with planned interim data in Q4 2025, and WTX‑330 has advanced to Phase 1b/2 with an update also planned in Q4 2025.
Werewolf Therapeutics furnished a press release announcing financial results for the quarter ended September 30, 2025.
The company reported this under Item 2.02 of an 8-K on November 4, 2025, and stated the information, including Exhibit 99.1, is furnished and not deemed filed under the Exchange Act.
The filing also includes a caution regarding forward-looking statements.
Werewolf Therapeutics (HOWL) director Luke Evnin reported open‑market sales of common stock made under a Rule 10b5‑1 plan dated September 24, 2025. The sales occurred on 10/30/2025, 10/31/2025, and 11/03/2025.
He sold 55,795 shares at a weighted average price of $1.43 (range $1.365–$1.55), 73,192 shares at $1.28 (range $1.205–$1.415), and 60,369 shares at $1.29 (range $1.245–$1.33). Following these transactions, 3,943,359 shares were reported as beneficially owned indirectly through affiliated entities.
Werewolf Therapeutics (HOWL): A reporting group affiliated with MPM BioImpact/MPM BioVentures, identified as a Director and 10% Owner, reported open‑market sales executed under a Rule 10b5‑1 plan dated September 24, 2025. The group sold 86,936 shares on 10/30/2025 at a weighted average price of $1.43, 114,044 shares on 10/31/2025 at $1.28, and 94,063 shares on 11/03/2025 at $1.29.
Following these transactions, the group reported indirect beneficial ownership of 6,355,717 shares, then 6,241,673 shares, and 6,147,610 shares, respectively. Footnotes state the sales were made across multiple affiliated entities, with price ranges of $1.365–$1.55 on 10/30, $1.205–$1.415 on 10/31, and $1.245–$1.33 on 11/03, and that each reporting person disclaims beneficial ownership beyond pecuniary interest.
Werewolf Therapeutics (HOWL): A director and 10% owner reported open‑market sales executed under a Rule 10b5‑1 plan dated September 24, 2025. The transactions were: 86,936 shares at a weighted average price of $1.43 on October 30, 2025; 114,044 shares at a weighted average price of $1.28 on October 31, 2025; and 94,063 shares at a weighted average price of $1.29 on November 3, 2025.
Following these sales, the filer reported 6,147,610 shares beneficially owned indirectly. The filing lists multiple affiliated entities as holders and confirms the plan‑based nature of the trades.
Werewolf Therapeutics (HOWL) director Luke Evnin reported open‑market sales of common stock executed under a Rule 10b5‑1 plan dated September 24, 2025.
He sold 46,664 shares on 10/27/2025 at a weighted average price of $1.72, 44,327 shares on 10/28/2025 at $1.64, and 86,154 shares on 10/29/2025 at $1.55. Following these transactions, he beneficially owned 4,132,715 shares indirectly.
Footnotes state the sales were made across affiliated entities and that prices reflect weighted averages with full trade‑level details available upon request.
Werewolf Therapeutics (HOWL): insider sales reported by MPM-affiliated holders. Reporting persons associated with MPM BioImpact/MPM BioVentures, identified as a Director and 10% Owner, disclosed open‑market sales executed pursuant to a Rule 10b5‑1 plan dated September 24, 2025.
Sales occurred on three dates: 72,709 shares on 10/27/2025 at a weighted average price of $1.72 (individual trades ranged $1.675–$1.82); 69,068 shares on 10/28/2025 at a weighted average price of $1.64 (range $1.605–$1.70); and 134,240 shares on 10/29/2025 at a weighted average price of $1.55 (range $1.51–$1.62).
Following these transactions, the reporting group’s beneficial ownership (indirect) was 6,645,961 shares after 10/27, 6,576,893 shares after 10/28, and 6,442,653 shares after 10/29, held across affiliated funds as detailed in the footnotes.
Werewolf Therapeutics (HOWL): Insider Form 4 filing reports sales by entities affiliated with MPM/UBS Oncology, identified as a director and 10% owner. The transactions were made pursuant to a Rule 10b5-1 plan dated September 24, 2025.
On October 27, 2025, 72,709 shares were sold at a weighted average price of $1.72 (range $1.675–$1.82), leaving 6,645,961 shares beneficially owned. On October 28, 2025, 69,068 shares were sold at a weighted average price of $1.64 (range $1.605–$1.70), leaving 6,576,893 shares beneficially owned. On October 29, 2025, 134,240 shares were sold at a weighted average price of $1.55 (range $1.51–$1.62), leaving 6,442,653 shares beneficially owned.
The filing attributes sales and post-transaction holdings across several affiliated funds and managers and notes that each reporting person disclaims beneficial ownership beyond their pecuniary interest.